William Blair reiterated their buy rating on shares of Pandora Media Inc (NYSE:P) in a research report sent to investors on Tuesday morning. On Friday shares of Pandora Media Inc (NYSE:P) closed at $16.44. Company’s sales growth for last 5 years was 75.60% and EPS growth for next 5 years is recorded as 43.03%.
On March 9, Gilead Sciences, Inc. (Nasdaq:GILD) announced that the Scottish Medicines Consortium (SMC) has approved Zydelig (idelalisib) – a new oral treatment – for adult patients with chronic lymphocytic leukaemia (CLL). Gilead Sciences Inc. (NASDAQ:GILD) in last trading activity moved down -0.32% to close at $99.61. Company weekly performance is -2.16% while its quarterly performance stands at -4.99%. Gilead Sciences Inc. (NASDAQ:GILD) is -14.74% away from its 52 week high.
On March 4, MoSys, Inc. (NASDAQ:MOSY) announced the closing of an underwritten public offering of 14,375,000 shares of its common stock at a price of $1.60 per share, less underwriting discounts and commissions. The shares sold in the offering reflected the underwriters’ exercise in full of their over-allotment option to purchase an additional 1,875,000 shares of common stock. After the underwriting discounts and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $21,300,000. On last trading day MoSys, Inc. (NASDAQ:MOSY) moved down -1.18% to close at $1.68. Its volatility for the week is 6.56% while volatility for the month is 6.67%. MOSY’s sales growth for past 5 years was -14.00% and its EPS growth for past 5 years was -1.60%. MoSys, Inc. (NASDAQ:MOSY) monthly performance is -20.00%.
Luby’s, Inc. (NYSE:LUB) announced that it will release 2015 fiscal second quarter financial results on Monday, March 23, 2015 before the market opens. In conjunction with the release, Luby’s has scheduled a conference call, which will be broadcast live over the Internet, on March 23. Luby’s, Inc. (NYSE:LUB) has 26.90% insider ownership while its institutional ownership stands at 43.60%. In last trading activity company’s stock closed at $5.35.
On March 9, it was reported that, The directors of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) shut down a shareholder derivative suit alleging Ariad’s leadership hid problems with a leukemia drug it eventually pulled from the market, sending the company to the brink of financial disaster, according to an order filed in Massachusetts federal court. On Friday shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) closed at $8.48. Company’s sales growth for last 5 years was 66.20% and EPS growth for next 5 years is recorded as 41.40%.